Neurocrine Biosciences
NBIX
NBIX
417 hedge funds and large institutions have $11.1B invested in Neurocrine Biosciences in 2020 Q2 according to their latest regulatory filings, with 89 funds opening new positions, 168 increasing their positions, 112 reducing their positions, and 36 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
417
Holders Change
+50
Holders Change %
+13.62%
% of All Funds
8.57%
Holding in Top 10
8
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-11.11%
% of All Funds
0.16%
New
89
Increased
168
Reduced
112
Closed
36
Calls
$71.2M
Puts
$65.4M
Net Calls
+$5.79M
Net Calls Change
-$3.17M
Top Buyers
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
$1.02B |
| 2 |
Invesco
Atlanta,
Georgia
|
$238M |
| 3 |
Renaissance Technologies
New York
|
$181M |
| 4 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
$111M |
| 5 |
BlackRock
New York
|
$916M |
Top Sellers
| 1 |
HM
HealthCor Management
New York
|
$43.4M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
$792M |
| 3 |
PA
Perceptive Advisors
New York
|
$261M |
| 4 |
Citadel Advisors
Miami,
Florida
|
$17.6M |
| 5 |
Victory Capital Management
San Antonio,
Texas
|
$78.4M |
